Skip to main content

Dr. Kathleen Neuzil, World-renowned Leader in Vaccine Research, Receives Moderna Vaccine

January 05, 2021 | January Payne

UMSOM Researchers Led Phase 3 Trial of Moderna Vaccine

Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine’s (UMSOM)’s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December.

Dr. Neuzil is a co-author of a new study in the New England Journal of Medicine that finds the Moderna vaccine has 94.1% efficacy in preventing illness from COVID-19, including severe disease. The study also found no safety concerns among those who were vaccinated, except for transient local and systemic reactions. Additionally, Dr. Neuzil currently serves as a member of the coronavirus vaccine working group for the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices and as the only U.S. member of the World Health Organization Strategic Advisory Group of Experts on Immunization.

CVD researchers at UMSOM led a Phase 3 clinical trial of this vaccine, which was co-developed by scientists at Moderna Inc. and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The vaccine trial was the first to be implemented under Operation Warp Speed, a multi-agency collaboration led by the U.S. Department of Health and Human Services, which aims to accelerate the development, manufacturing, and distribution of medical countermeasures for COVID-19.

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $563 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

Contact

January Payne
Director of Public Relations
(443) 203-8183
january.payne@som.umaryland.edu

Related stories

    Wednesday, June 09, 2021

    Global Study of Microbes in 60 Cities Finds Each Has Unique Fingerprint of Viruses and Bacteria

    Each city has its own unique microbiome, a “fingerprint” of viruses and bacteria that serves as type of city profile, according to a new study from an international consortium of researchers that included a team from the University of Maryland School of Medicine (UMSOM). The international project, which sequenced and analyzed samples collected from public transit systems and hospitals in 60 cities around the world, was published today in the journal Cell.


    Tuesday, March 16, 2021

    New Study Finds Healthcare Settings Do Not Pose Added Risk Factor for Covid-19 Infection Spread Among U.S. Healthcare Personnel

    Healthcare personnel who were infected with COVID-19 faced stronger risk factors outside of the workplace than in their hospital or healthcare settings. That is the finding of a new study published today in the Journal of the American Medical association's JAMA Network Open conducted by University of Maryland School of Medicine (UMSOM) researchers and colleagues at the Centers for Disease Control and Prevention (CDC) and three other universities.


    Wednesday, January 27, 2021

    Dr. Wilbur Chen, Nationally-Recognized Vaccine Researcher, Selected for Federal Committee that Guides Immunization Policies

    Wilbur H. Chen, MD, MS, FIDSA, FACP, Professor of Medicine at the University of Maryland School of Medicine (UMSOM), has been named a new voting member of the federal government’s Advisory Committee on Immunization Practices (ACIP), the prestigious board of experts that makes recommendations on the safe use of vaccines for Americans. The U.S. Department of Health and Human Services selected Dr. Chen for the 15-member advisory committee based on his expertise and national leadership in vaccinology, infectious diseases, public health, and preventive medicine. He will remain in his current role at UMSOM while he serves in his four-year term, which began last month.


    Thursday, January 21, 2021

    UM School of Medicine Hosted Media Availability for Ensuring Trust in COVID-19 Vaccine Event

    On January 22, 2021 at 2 p.m., the University of Maryland School of Medicine (UMSOM) hosted Black faith-based leaders, COVID-19 research volunteers, and “America’s Doctor,” Anthony Fauci, MD. The event provided straight talk about fears, trust issues, and why we need our Black and Brown community to be a part of COVID-19 vaccine research.


    Tuesday, January 05, 2021

    University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate

    Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD.


    Thursday, November 19, 2020

    Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine

    Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19.


    Friday, November 13, 2020

    UM School of Medicine and School of Pharmacy Researchers Identify Promising New Compounds to Potentially Treat Novel Coronaviruses

    Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The compounds disrupt the functioning of a protein complex inside human cells that the researchers discovered is critical for the replication and survival of coronaviruses. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses, according to a new study published today in the Proceedings of the National Academy of Sciences (PNAS) journal.


    Tuesday, June 16, 2020

    UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19

    Researchers at the University of Maryland School of Medicine (UMSOM) will be partnering on an agreement funded by the federal government’s Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19. The compounds will be tested in studies using state-of-the-art technologies in the laboratory of coronavirus researcher Matthew Frieman, PhD., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. UMSOM will receive up to $3.6 million over the next year to fund this effort.


    Tuesday, June 02, 2020

    UM School of Medicine’s Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa

    The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique.


    Monday, June 01, 2020

    In A COVID-19 World, Another Threat to the Health of Our Children

    In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations.


    Thursday, May 28, 2020

    UM School of Medicine Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique

    Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society’s nanotechnology journal ACS Nano.


    Thursday, May 21, 2020

    UM School of Medicine Begins First Innovative Trial of Experimental Stem Cell Therapy to Reduce Deaths in Sickest COVID-19 Patients

    Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. The trial, which is being conducted at the University of Maryland Medical Center (UMMC) and additional sites across the U.S, will involve a total of 300 patients randomized to receive either the drug remestemcel-L or a placebo in addition to the recommended standard of care to manage severe COVID-19 infections. The first patient in this national trial was treated at UMMC.


    Tuesday, May 05, 2020

    UM School of Medicine is First in U.S. to Test Unique RNA Vaccine Candidate for COVID-19

    In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine.


    Thursday, April 23, 2020

    UM School of Medicine Researchers Test Remdesivir as Potential Therapy for COVID-19 Patients

    Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).


    Friday, April 10, 2020

    University of Maryland School of Medicine Launches New Large Scale COVID-19 Testing Initiative

    University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland.


    Monday, May 15, 2017

    UM SOM Vaccine Researcher Receives Top Award in the Study of Infectious Diseases

    Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor and Associate Dean for Global Health, Vaccinology and Infectious Disease at UM SOM, has been awarded the Maxwell Finland Award for Scientific Achievement by the National Foundation for Infectious Diseases (NFID). The award honors his extensive accomplishments in public health; over his career, he has identified solutions to major sources of disease in the developing world, including cholera, typhoid, and Shigella dysentery. The award will be presented on Thursday, May 18, 2017 at the Hyatt Regency Bethesda in Bethesda, Md.


    Friday, April 14, 2000

    Letter from Dean Reece to FPI Patients

    The COVID-19 pandemic has changed many aspects of our lives, from the way we shop and eat to how we connect with family and friends. While the virus itself has had strong and sometimes devastating effects on our community, the fear of its potential impact continues to influence responses and even cripple thoughts and actions.